Primary Gene Structure and Expression Studies of Rodent Paracellin-1

Total Page:16

File Type:pdf, Size:1020Kb

Primary Gene Structure and Expression Studies of Rodent Paracellin-1 J Am Soc Nephrol 12: 2664–2672, 2001 Primary Gene Structure and Expression Studies of Rodent Paracellin-1 STEFANIE WEBER,* KARL P. SCHLINGMANN,* MELANIE PETERS,* LENE NIEMANN NEJSUM,† SØREN NIELSEN,† HARTMUT ENGEL,‡ KARL-HEINZ GRZESCHIK,‡ HANNSJO¨ RG W. SEYBERTH,* HERMANN-JOSEPH GRO¨ NE,§ ROLF NU¨ SING,* and MARTIN KONRAD* *Department of Pediatrics, Philipps University, Marburg, Germany; †Department of Cell Biology, Institute of Anatomy, University of Aarhus, Aarhus, Denmark; ‡Institute of Human Genetics, Philipps University, Marburg, Germany; and §Deutsches Krebsforschungszentrum, Heidelberg, Germany. Abstract. The novel member of the claudin multigene family, lengths and splice-site loci. By radiation hybrid mapping, the paracellin-1/claudin-16, encoded by the gene PCLN1, is a renal murine Pcln1 gene was assigned directly to marker D16Mit133 tight junction protein that is involved in the paracellular trans- on mouse chromosome 16 (syntenic to a locus on human port of magnesium and calcium in the thick ascending limb of chromosome 3q27, which harbors the human PCLN1 gene). Henle’s loop. Mutations in human PCLN1 are associated with Mouse multiple-tissue Northern blot showed Pcln1 expression familial hypomagnesemia with hypercalciuria and nephrocal- exclusively in the kidney. The expression profile along the cinosis, an autosomal recessive disease that is characterized by nephron was analyzed by reverse transcriptase–PCR on micro- severe renal magnesium and calcium loss. The complete cod- dissected nephron segments and immunohistochemistry of rat ing sequences of mouse and rat Pcln1 and the murine genomic kidney. Paracellin-1 expression was restricted to distal tubular structure are here presented. Full-length cDNAs are 939 and segments including the thick ascending limb of Henle’s loop, 1514 bp in length in mouse and rat, respectively, encoding a the distal tubule, and the collecting duct. The identification and putative open-reading frame of 235 amino acids in both species characterization of the rodent Pcln1 genes provide the basis for with 99% identity. Exon-intron analysis of the human and further studies of paracellin-1 function in suitable animal mouse genes revealed a 100% homology of coding exon models. Members of the claudin multigene family have been identified fied in the kidney, especially in the thick ascending limb of as essential components of the endothelial and epithelial tight Henle’s loop (TALH) (4). junction barrier. In 1998, claudin-1 and claudin-2 were first Mutations in PCLN1 were found to be associated with described by Furuse et al. (1) and were colocalized with the familial hypomagnesemia with hypercalciuria and nephrocal- ubiquitous tight junction protein occludin to cell-to-cell adhe- cinosis (FHHNC, OMIM 248250), a hereditary renal disease sions in chicken liver. Since then, a great number of proteins with urinary magnesium and calcium loss and progression to with related structure were identified in tight junction strands end-stage renal failure (4,7,8). As concluded from the pheno- of multiple tissues (2,3); some of them associated with hered- type of FHHNC patients, an important role of paracellin-1 in itary diseases in humans (4–6). All claudins represent mem- the regulation of paracellular transport of divalent cations in brane proteins with four transmembrane domains, two extra- the TALH was suggested. Little is known about human mag- cellular loops, and intracellular N- and C-termini. Recently, nesium transport mechanisms; therefore, the identification of paracellin-1/claudin-16, which is encoded by the gene PCLN1, paracellin-1 represented a major step to elucidate the mecha- was characterized as a new member of this protein family in nisms of renal magnesium reabsorption. The bovine PCLN1 humans. Although other members of the claudin family show gene was recently identified, and PCLN1 deletions were de- a wide tissue distribution, paracellin-1 was exclusively identi- scribed in Japanese Black cattle affected by an autosomal- recessive renal disorder (9,10). Renal histology in these ani- mals showed a tubular atrophy associated with interstitial nephritis, pointing to an additional role of paracellin-1 for renal Received May 25, 2001. Accepted July 10, 2001. Correspondence to Dr. Martin Konrad, Department of Pediatrics, Philipps epithelial integrity. University Marburg, Deutschhausstrasse 12, D-35037 Marburg, Germany. To provide the basis for further studies of paracellin-1 in Phone: 49-6421-2862789; Fax: 49-6421-2865724; E-mail: konradm@ suitable animal models we performed a cloning strategy of the mailer.uni-marburg.de homologous genes in mouse and rat. We here present the S.W. and K.P.S. contributed equally to this work. cDNA sequences of mouse and rat Pcln1, the murine genomic 1046-6673/1212-2664 Journal of the American Society of Nephrology structure, and the results of RNA and protein expression Copyright © 2001 by the American Society of Nephrology studies. J Am Soc Nephrol 12: 2664–2672, 2001 Paracellin-1 in Mouse and Rat 2665 Materials and Methods BLAST programs that are supplied by NCBI and Infobiogen web sites Cloning of Mouse and Rat Pcln1 cDNA (http://www.ncbi.nlm.nih.gov; http://www.infobiogen.fr). Protein pat- To obtain the cDNA sequences of mouse and rat Pcln1, a search tern and statistical protein structure analysis were performed by using with the coding sequence of human PCLN1 was performed in mouse the PROSITE protein pattern search tools (www.expasy.ch/prosite). and rat EST databases, which yielded five different mouse EST clones (EMBL/GenBank/DDBJ Accession no. BB499021, BB501602, BB Determination of Exon-Intron Boundaries of Mouse 0496375, BB498218, and AV380228) sequenced from the 3'-end Pcln1 corresponding to bases 790 to 989 of the human PCLN1 cDNA To determine the exon-intron boundaries of murine introns two, (EMBL/GenBank/DDBJ Accession no. AF152101) and two different three, and four, exon-specific primers were designed and the inter- rat EST clones comprising the 3'-end of rat Pcln1 (EMBL/GenBank/ vening intron sequences amplified from mouse genomic DNA with DDBJ Accession no. AI412107 and AW142781). the Expand Long Template PCR System (Roche Diagnostics GmbH, By 5'–RACE-PCR (rapid amplification of cDNA ends) the lacking Mannheim, Germany). The fragments were run on an agarose gel, and 5'-region was amplified from mouse kidney Marathon Ready cDNA the approximate sizes were determined by using a half-logarithmic (Clontech, Palo Alto, CA) with the Advantage II Polymerase Mix function. The exon-intron boundaries of these introns were sequenced (Clontech) by using the mouse gene–specific primer mmGSP1 (for all directly with exon-specific primers. primer sequences see Table 1). A Southern blot procedure was used to The exon-intron boundaries of intron one were determined by using identify the correct PCR-fragment (ECL-3'–oligolabeling and detec- the Mouse Genome Walker Kit (Clontech). The nested PCR reaction tion systems; Amersham Pharmacia Biotech, Uppsala, Sweden) (re- yielded a single fragment that was subcloned into the pCR2.1-TOPO sults not shown). A mouse gene–specific primer, mmGSP2, was vector and sequenced from both strands. Alignment with human designed from the 5'-RACE product, and an additional 3'-RACE-PCR PCLN1 was performed with the CLUSTALW-program (http://clust- performed to obtain the complete full-length downstream sequence. alw.genome.ad.jp). The human gene structure was obtained by search The 784-bp and 485-bp PCR fragments were agarose gel purified, in human genomic databases with the human cDNA sequence and by subcloned into a pCR2.1-TOPO vector (Invitrogen, Groningen, The location of the human PCLN1 gene in GenBank contigs AC009520 Netherlands), and sequenced from both strands by using the ABI and AC073963. PRISM 310 Genetic Analyzer (Applera, Norwalk, CT). The 5'– and 3'–RACE-PCR from rat kidney cDNA were performed Chromosomal Assignment of Mouse Pcln1 analogously with rat gene–specific primers rnGSP1 and rnGSP2, The genetic map position of mouse Pcln1 was determined by respectively. The 814-bp and 871-bp PCR fragments were subcloned segregation analysis by using gene-specific amplification of clone and sequenced as described above. DNA from the Whitehead Institute Center for Genomic Research The cDNA sequence of full-length murine Pcln1 was deposited mouse radiation hybrid mapping panel (11). The primer pair mm-Int4- with GenBank accession no. AF323748 and the full-length rat cDNA F/R spanning intron 4 of mouse Pcln1 was used for amplification sequence with accession no. AF333099. (fragment size, Ϸ1350 bp). Data vectors, which were based on two independent PCR analyses of the entire panel, with data arranged in Analysis of cDNA and Amino Acid Sequences the order specified for the Whitehead Institute/MIT Center for Ge- The final cDNA and amino acid sequences obtained were com- nome Research, Mouse EST RH Mapping Project, Public Data Re- pared with human and bovine PCLN1 by using the FASTA and lease 3 (April, 2000) were submitted to two-point maximum-likeli- Table 1. Oligonucleotide sequences used for PCR, rapid amplification of cDNA ends–PCR, and reverse transcriptase–PCR Primer Designation Sequence Product Length (bp) mmGSP 1 5Ј-GGGTAGTTCCTCTCAGGCCCAACATCT-3Ј 784 mmGSP 2 5Ј-CTGTGGATGTTTACGTCGAACGCTCCT-3Ј 485 rnGSP 1 5Ј-AGGAGCGTTCGACGTAAACATCCACAG-3Ј 814 rnGSP 2 5Ј-TTGACTGCGTGAAGTTCCTACCGGATG-3Ј 871 mm-Int1F-GW-1 5Ј-TCTTCTTCAGTACGCTGCCTGCTTCT-3Ј mm-Int1F-GW-2 5Ј-TTGGCCATATTCTCCACTGGGTTTTT-3Ј mm-Int1R-GW-1 5Ј-TATGGAGTCGTACTCATCGCAGGTTC-3Ј mm-Int1R-GW-2 5Ј-GAATCCCATCAAAAGCGTTTGTTACAC-3Ј mm-Int2-F 5Ј-ACCTGCGATGAGTACGACTCC-3ЈϷ3300 mm-Int2-R 5Ј-GATCATCAGTGCTCGAGTTACCAC-3Ј mm-Int3-F 5Ј-CTTTGTTGCAGGGACCACATTACTC-3ЈϷ3650 mm-Int3-R 5Ј-AGCATACCACACAGAACCGATGATT-3Ј mm-Int4-F 5Ј-CTCACCTGCTGTTTGTACCTCTTC-3ЈϷ1350 mm-Int4-R 5Ј-TGCAGTTGAATAGGGCTTCC-3Ј rn-PC-RT-F 5Ј-TTGTTGCAGGGACCGTATTACTCA-3Ј 248 rn-PC-RT-R 5Ј-GGGTAGTTCCTCTCAGGTCCAACA-3Ј rn-␤A-RT-F 5Ј-GAGTACAACCTCCTTGCAGCTC-3Ј 329 rn-␤A-RT-R 5Ј-TTGTAGAAAGTGTGGTGCCAAA-3Ј 2666 Journal of the American Society of Nephrology J Am Soc Nephrol 12: 2664–2672, 2001 hood analysis (http://www.genome.wi.mit.edu/cgi-bin/mouse_rh/ Solubilization of Rat Kidney Proteins rhmap-auto/rhmapper.cgi).
Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • Claudin-1, -3 and -4 Proteins and Mrna Expression in Benign and Malignant Breast Lesions: a Research Study
    Available online http://breast-cancer-research.com/content/7/2/R296 ResearchVol 7 No 2 article Open Access Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study Anna-Mária Tőkés1*, Janina Kulka1*, Sándor Paku2, Ágnes Szik1, Csilla Páska1, Pál Kaposi Novák1, László Szilák1, András Kiss1, Krisztina Bögi1 and Zsuzsa Schaff1 12nd Department of Pathology, Semmelweis University, Budapest, Hungary 2Department of Molecular Pathology, Joint Research Organization of the Hungarian Academy of Sciences, Budapest, Hungary * Contributed equally Corresponding author: Janina Kulka, [email protected] Received: 23 Jan 2004 Revisions requested: 15 Mar 2004 Revisions received: 1 Oct 2004 Accepted: 2 Dec 2004 Published: 31 Jan 2005 Breast Cancer Research 2005, 7:R296-R305 (DOI 10.1186/bcr983)http://breast-cancer-research.com/content/7/2/R296 © 2005 Tőkés et al., licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited. Abstract Introduction We compared levels of protein and mRNA CLDN4 was present in all 56 tissue sections. However, CLDN4 expression of three members of the claudin (CLDN) family in was highly positive in normal epithelial cells and was decreased malignant breast tumours and benign lesions. or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in Methods Altogether, 56 sections from 52 surgically resected areas of apocrine metaplasia.
    [Show full text]
  • Identification of Claudin 1 Transcript Variants in Human Invasive Breast Cancer
    RESEARCH ARTICLE Identification of Claudin 1 Transcript Variants in Human Invasive Breast Cancer Anne A. Blanchard1,2, Teresa Zelinski3,4, Jiuyong Xie2, Steven Cooper1, Carla Penner1, Etienne Leygue4,5, Yvonne Myal1,2,5* 1 Department of Pathology, University of Manitoba, Winnipeg, Manitoba, Canada, 2 Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Manitoba, Canada, 3 Departmentof Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada, 4 Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada, 5 Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada * [email protected] a11111 Abstract Background The claudin 1 tight junction protein, solely responsible for the barrier function of epithelial cells, is frequently down regulated in invasive human breast cancer. The underlying mecha- OPEN ACCESS nism is largely unknown, and no obvious mutations in the claudin 1 gene (CLDN1) have Citation: Blanchard AA, Zelinski T, Xie J, Cooper S, been identified to date in breast cancer. Since many genes have been shown to undergo Penner C, Leygue E, et al. (2016) Identification of deregulation through splicing and mis-splicing events in cancer, the current study was Claudin 1 Transcript Variants in Human Invasive undertaken to investigate the occurrence of transcript variants for CLDN1 in human invasive Breast Cancer. PLoS ONE 11(9): e0163387. breast cancer. doi:10.1371/journal.pone.0163387 Editor: Amanda Ewart Toland, Ohio State University Wexner Medical Center, UNITED STATES Methods Received: May 17, 2016 RT-PCR analysis of CLDN1 transcripts was conducted on RNA isolated from 12 human invasive breast tumors. The PCR products from each tumor were resolved by agarose gel Accepted: September 6, 2016 electrophoresis, cloned and sequenced.
    [Show full text]
  • Identification of Potential Core Genes in Sevoflurance Induced Myocardial
    Identication of Potential core genes in Sevourance induced Myocardial Energy Metabolism in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery using Bioinformatics analysis Hua Lin ( [email protected] ) Tianjin Medical University General Hospital Airport Site Research article Keywords: sevourane, Myocardial Energy Metabolism, Off-pump Coronary Artery Bypass Graft Surgery Posted Date: November 18th, 2019 DOI: https://doi.org/10.21203/rs.2.17434/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Background: Myocardial ischemia-reperfusion injury always happened after Off-pump coronary artery bypass graft(OPCABG), and this can not be avoided altogether. In this study, we tried to detect potential genes of sevourane-induced myocardial energy metabolism in patients undergoing OPCABG using bioinformatics analysis. Methods: We download and analyze the gene expression prole data from the Gene Expression Omnibus(GEO) database using bioinformatics methods. We downloded the gene expression data from the Gene Expression Omnibus(GEO) database using bioinformatics methods. Gene Ontology(GO) functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis were used to analysis the screened differentially expressed genes(DEGs). Then, we established a protein–protein interaction (PPI) network to nd hub genes associated with myocardial energy metabolism. Results: Through PPI network, we nd ten hub genes, including JUN, EGR1, ATF3, FOSB, JUNB, DUSP1, EGR2, NR4A1, BTG2, NR4A2. Conclusions: In conclusion, the proteins encoded by EGR1ATF3c-FosBtg2JunBDUSP1NR4A1BTG2 and NR4A2 were related to cardiac function. ATF3, FOSB, JUNB, DUSP1, NR4A1, NR4A2 are related to apoptosis of cardiomyocytes. The protein encoded by BTG2 is related to hypertrophy.
    [Show full text]
  • Claudin-1, a Double-Edged Sword in Cancer
    International Journal of Molecular Sciences Review Claudin-1, A Double-Edged Sword in Cancer Ajaz A. Bhat 1 , Najeeb Syed 1, Lubna Therachiyil 2,3, Sabah Nisar 1, Sheema Hashem 1, Muzafar A. Macha 4,5, Santosh K. Yadav 1, Roopesh Krishnankutty 2, Shanmugakonar Muralitharan 6, Hamda Al-Naemi 6, Puneet Bagga 7, Ravinder Reddy 7, Punita Dhawan 5, Anthony Akobeng 8, Shahab Uddin 2 , Michael P. Frenneaux 9, Wael El-Rifai 10 and Mohammad Haris 1,6,* 1 Division of Translational Medicine, Research Branch, Sidra Medicine, Doha 26999, Qatar; [email protected] (A.A.B.); [email protected] (N.S.); [email protected] (S.N.); [email protected] (S.H.); [email protected] (S.K.Y.) 2 Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha 3050, Qatar; [email protected] (L.T.); [email protected] (R.K.); [email protected] (S.U.) 3 Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha 2713, Qatar 4 Department of Biotechnology, Central University of Kashmir, Ganderbal, Jammu and Kashmir 191201, India; [email protected] 5 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA; [email protected] 6 Laboratory Animal Research Center, Qatar University, Doha 2713, Qatar; [email protected] (S.M.); [email protected] (H.A.-N.) 7 Center for Magnetic Resonance and Optical Imaging, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; [email protected]
    [Show full text]
  • Antibody Tools Immunohistochemistry
    Antibody Tools Immunohistochemistry $$ 250 - 150 - 100 - 75 - 50 - 37 - Western Blot 25 - 20 - 15 - 10 - 1.4 1.2 1 0.8 0.6 OD 450 0.4 Sandwich ELISA 0.2 0 0.01 0.1 1 10 100 1000 Recombinant Protein Concentration(mg/ml) Immunohistochemistry Immunofluorescence 1 2 3 250 - 150 - 100 - 75 - 50 - Immunoprecipitation 37 - 25 - 20 - 15 - 100 80 60 % of Max 40 Flow Cytometry 20 0 3 4 5 0 102 10 10 10 www.abnova.com March 2013 (Sixth Edition) Abnova Corporation www.abnova.com Email: [email protected] Address: 9F, No. 108, Jhouzih St., Neihu, Taipei 114, Taiwan Tel: + 886 2 8751 1888 Fax: + 886 2 6602 1218 Antibodies tool for IHC, Class I IVD (In Vitro Diagnostics) Cat. Num. DH0003 DH0013 DH0020 DH0015 Product Name Anti-ACTN4 monoclonal antibody Anti-ANXA5 monoclonal antibody Anti-CDH17 monoclonal antibody Anti-CLDN1 monoclonal antibody Application Immunoperoxidase of monoclonal antibody Immunoperoxidase of monoclonal antibody to Immunoperoxidase of monoclonal antibody to Immunoperoxidase of monoclonal antibody to to ACTN4 on formalin-fixed paraffin- ANXA5 on formalin-fixed paraffin-embedded CDH17 on formalin-fixed paraffin-embedded CLDN1 on formalin-fixed paraffin-embedded embedded human pancreatic cancer. [antibody human colon cancer. [antibody concentration 3 human colon cancer. [antibody concentration 3 human colon cancer. [antibody concentration 3 concentration 1.5 ug/ml] ug/ml] ug/ml] ug/ml] Cat. Num. DH0002 DH0021 DH0010 DH0017 Product Name Anti-CTH monoclonal antibody Anti-EGR1 monoclonal antibody Anti-EIF2C2 monoclonal antibody Anti-ENO1 monoclonal antibody Application Immunoperoxidase of monoclonal antibody Immunoperoxidase of monoclonal antibody Immunoperoxidase of monoclonal antibody to Immunoperoxidase of monoclonal antibody to CTH on formalin-fixed paraffin-embedded to EGR1 on formalin-fixed paraffin-embedded EIF2C2 on formalin-fixed paraffin-embedded to ENO1 on formalin-fixed paraffin-embedded human liver.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Chromosome Transfer Induced Aneuploidy Results in Complex Dysregulation of the Cellular Transcriptome in Immortalized and Cancer Cells
    [CANCER RESEARCH 64, 6941–6949, October 1, 2004] Chromosome Transfer Induced Aneuploidy Results in Complex Dysregulation of the Cellular Transcriptome in Immortalized and Cancer Cells Madhvi B. Upender,1 Jens K. Habermann,1,4 Lisa M. McShane,3 Edward L. Korn,3 J. Carl Barrett,2 Michael J. Difilippantonio,1 and Thomas Ried1 1Genetics Branch and 2Laboratory for Biosystems and Cancer, Center for Cancer Research and 3Biometric Research Branch, National Cancer Institute/NIH, Bethesda, Maryland; and 4Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden ABSTRACT tumor cells (4, 18–20). Additionally, in cell culture model systems in which cells are exposed to different carcinogens, chromosomal ane- Chromosomal aneuploidies are observed in essentially all sporadic uploidy is the earliest detectable genomic aberration (21, 22). carcinomas. These aneuploidies result in tumor-specific patterns of The conservation of these tumor and tumor-stage–specific patterns genomic imbalances that are acquired early during tumorigenesis, con- tinuously selected for and faithfully maintained in cancer cells. Although of chromosomal aneuploidies suggests that they play a fundamental the paradigm of translocation induced oncogene activation in hematologic biological role in tumorigenesis. It remains, however, unresolved how malignancies is firmly established, it is not known how genomic imbal- such genomic imbalances affect global gene expression patterns. One ances affect chromosome-specific gene expression patterns in particular could postulate that expression levels of all transcriptionally active and how chromosomal aneuploidy dysregulates the genetic equilibrium of genes on trisomic chromosomes would increase in accordance with cells in general. To model specific chromosomal aneuploidies in cancer the chromosome copy number.
    [Show full text]
  • Identification of Claudin‑1, ‑3, ‑7 and ‑8 As Prognostic Markers in Human Laryngeal Carcinoma
    MOLECULAR MEDICINE REPORTS 20: 393-400, 2019 Identification of claudin‑1, ‑3, ‑7 and ‑8 as prognostic markers in human laryngeal carcinoma SHU ZHOU1, XUE PIAO2, CHENGYAN WANG3, RUI WANG3 and ZHIMIN SONG4 1Department of Anesthesiology, Jilin Cancer Hospital; 2Department of Anesthesiology, Maternity Hospital of Changchun City; 3Department of Ultrasound, Jilin Cancer Hospital; 4Department of Anesthesiology, The Second Hospital of Jilin University, Changchun, Jilin 130021, P.R. China Received June 20, 2018; Accepted February 8, 2019 DOI: 10.3892/mmr.2019.10265 Abstract. Various genomic and epigenetic modifications demonstrated that the expression levels of CLDN1, -3, -7 and that occur during the development of cancer act as potential -8 varied between laryngeal squamous carcinoma tissues and biomarkers for early diagnosis and treatment. Previous studies non-neoplastic tissues. The expression levels of these CLDNs have demonstrated abnormal expression of the claudin (CLDN) may be useful molecular markers for the diagnosis of laryngeal tight junction (TJ) proteins in numerous types of human carcinoma, and determining the metastasis and prognosis of this cancer. Reverse transcription-quantitative polymerase chain disease. reaction and western blotting were employed to investigate variations in the expression of the CLDN TJ proteins in laryn- Introduction geal non-neoplastic tissues and laryngeal squamous carcinoma tissues. It was revealed that CLDN2, CLDN4, CLDN5, CLDN6, Tight junctions (TJs) form the apical junctional complex in epithe- CLDN9, CLDN11 and CLDN12 were undetectable in laryngeal lial and endothelial cellular sheets in cooperation with adherens squamous carcinoma tissues and laryngeal non-neoplastic junctions and desmosomes (1). TJs are important for the tight tissues. Additionally, CLDN10 was expressed in laryngeal squa- structure of cellular sheets, which enables monitored paracel- mous carcinoma tissues and laryngeal non-neoplastic tissues; lular ion flux and the maintenance of tissue homeostasis (2).
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • Supplementary Data
    Supplementary figure 1. Concordance between HER-2 amplification measured by FISH and CGH 5 4 6) 3 14_P11482 __ 2 Log2(3) atio probe A atio probe rr 1 Log2(1.5) array Log2( CGH 0 -1 0 1 2 3 4 Er bb2 non amplifi e d Erbb2 amplified -1 FISH Log2 (ERBB2 gene copies) Supplementary Figure 2. Gained and lost regions according to triple-negativity Non-triple negative tumors (n=69) Triple negative tumors (n=35) Non-triple negative tumors (n=69) vs triple negative tumors (n=35) Supplementary Figure 3. Gained and lost regions according to chemotherapy response Supplementary Figure 4. Gained and lost regions according to taxanes efficacy Supplementary Table 1. Patient characteristics (n=106). Characteristic N (%) Age (median, range) 51 (28-73) cT cT0/T1 6 (6%) cT2 53 (50%) cT3 18 (17%) cT4 29 (17%) cN cN0 24 (23%) cN1 50 (47%) cN2 23 (22%) cN3 9 (8%) Tumor grade Grade 1 6 (6%) Grade 2 39 (37%) Grade 3 47 (43%) Not assessable 14 (14%) Estrogen receptor expression Negative 45 (42%) Positive 60 (57%) Unknown 1 (1%) Progesteron receptor expression Negative 57 (54%) Positive 47 (44%) Unknown 2 (2%) Her2 status Normal 95 (90%) Overexpression and/or amplification 11 (10%) Preoperative chemotherapy T/FAC* 66 (62%) FAC 38 (36%) Trastuzumab-containing regimen 2 (2%) Pathologic complete remission No 83 (78%) Yes 20 (19%) Not assessable 3 (3%) *: Sequential Paclitaxel / FAC (or FEC) or docetaxel /FEC (n=2) Supplementary Table 2. Minimum Common region (MCR) gained in more than 20% of samples: Band1 Probes Freq Genes AP2M1 CLCN2 DVL3 EIF4G1 EPHB3 POLR2H PSMD2 THPO
    [Show full text]